Browsing Tag
GT801
1 post
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.